- Home
- FTHY vs TBPH Comparison
FTHY vs TBPH Comparison
Compare FTHY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- TBPH
- Stock Information
- Founded
- FTHY 2020
- TBPH 2013
- Country
- FTHY United States
- TBPH United States
- Employees
- FTHY N/A
- TBPH N/A
- Industry
- FTHY Investment Managers
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- TBPH Health Care
- Exchange
- FTHY Nasdaq
- TBPH Nasdaq
- Market Cap
- FTHY 533.6M
- TBPH 464.5M
- IPO Year
- FTHY N/A
- TBPH N/A
- Fundamental
- Price
- FTHY $14.43
- TBPH $9.00
- Analyst Decision
- FTHY
- TBPH Buy
- Analyst Count
- FTHY 0
- TBPH 4
- Target Price
- FTHY N/A
- TBPH $13.75
- AVG Volume (30 Days)
- FTHY 176.7K
- TBPH 190.1K
- Earning Date
- FTHY 01-01-0001
- TBPH 05-12-2025
- Dividend Yield
- FTHY 10.93%
- TBPH N/A
- EPS Growth
- FTHY N/A
- TBPH N/A
- EPS
- FTHY N/A
- TBPH N/A
- Revenue
- FTHY N/A
- TBPH $64,381,000.00
- Revenue This Year
- FTHY N/A
- TBPH $39.34
- Revenue Next Year
- FTHY N/A
- TBPH $3.63
- P/E Ratio
- FTHY N/A
- TBPH N/A
- Revenue Growth
- FTHY N/A
- TBPH 12.12
- 52 Week Low
- FTHY $12.66
- TBPH $7.44
- 52 Week High
- FTHY $14.74
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- FTHY 44.68
- TBPH 41.51
- Support Level
- FTHY $14.40
- TBPH $9.05
- Resistance Level
- FTHY $14.66
- TBPH $9.55
- Average True Range (ATR)
- FTHY 0.12
- TBPH 0.24
- MACD
- FTHY 0.01
- TBPH -0.03
- Stochastic Oscillator
- FTHY 29.58
- TBPH 12.82
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).